COMPIT Project
Drug-Induced Tissue Damage (Immunological Risk Assessment)
PreclinicalCompleted
Key Facts
Indication
Drug-Induced Tissue Damage (Immunological Risk Assessment)
Phase
Preclinical
Status
Completed
Company
About Immunosys
Founded in 2016 and based in London/Manchester, Immunosys is a specialized scientific consulting firm and partial owner of a preclinical CRO, focusing on immunology and infectious disease. Its core business model is providing high-level consulting services and laboratory work to support drug discovery, particularly in developing novel in vitro human cellular systems for assessing immunological risk. The company has demonstrated capability through completed grant-funded R&D projects, positioning itself as an expert partner in human in vitro biology for biopharma clients.
View full company profile